X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs GSK PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES GSK PHARMA DIVIS LABORATORIES/
GSK PHARMA
 
P/E (TTM) x 28.7 62.4 46.0% View Chart
P/BV x 5.0 10.0 49.6% View Chart
Dividend Yield % 1.0 1.3 79.0%  

Financials

 DIVIS LABORATORIES   GSK PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
GSK PHARMA
Mar-17
DIVIS LABORATORIES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2223,838 31.8%   
Low Rs7842,637 29.7%   
Sales per share (Unadj.) Rs153.1354.2 43.2%  
Earnings per share (Unadj.) Rs39.939.8 100.5%  
Cash flow per share (Unadj.) Rs44.642.9 104.0%  
Dividends per share (Unadj.) Rs10.0030.00 33.3%  
Dividend yield (eoy) %1.00.9 107.6%  
Book value per share (Unadj.) Rs201.8236.9 85.2%  
Shares outstanding (eoy) m265.4784.70 313.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.69.1 71.7%   
Avg P/E ratio x25.181.4 30.8%  
P/CF ratio (eoy) x22.575.5 29.8%  
Price / Book Value ratio x5.013.7 36.4%  
Dividend payout %25.075.4 33.2%   
Avg Mkt Cap Rs m266,266274,216 97.1%   
No. of employees `0009.74.7 207.3%   
Total wages/salary Rs m4,6874,830 97.0%   
Avg. sales/employee Rs Th4,175.06,387.0 65.4%   
Avg. wages/employee Rs Th481.51,028.3 46.8%   
Avg. net profit/employee Rs Th1,089.3717.1 151.9%   
INCOME DATA
Net Sales Rs m40,64330,000 135.5%  
Other income Rs m749728 102.8%   
Total revenues Rs m41,39230,728 134.7%   
Gross profit Rs m14,4604,190 345.1%  
Depreciation Rs m1,233263 468.9%   
Interest Rs m230-   
Profit before tax Rs m13,9534,655 299.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m3,3491,744 192.0%   
Profit after tax Rs m10,6043,368 314.9%  
Gross profit margin %35.614.0 254.8%  
Effective tax rate %24.037.5 64.1%   
Net profit margin %26.111.2 232.4%  
BALANCE SHEET DATA
Current assets Rs m40,10516,742 239.5%   
Current liabilities Rs m6,5957,202 91.6%   
Net working cap to sales %82.531.8 259.3%  
Current ratio x6.12.3 261.6%  
Inventory Days Days11952 228.8%  
Debtors Days Days8121 388.3%  
Net fixed assets Rs m19,9958,635 231.6%   
Share capital Rs m531847 62.7%   
"Free" reserves Rs m53,04319,222 276.0%   
Net worth Rs m53,57420,069 267.0%   
Long term debt Rs m010 0.0%   
Total assets Rs m61,58530,038 205.0%  
Interest coverage x618.4NM-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.71.0 66.1%   
Return on assets %17.311.2 153.9%  
Return on equity %19.816.8 117.9%  
Return on capital %26.125.5 102.5%  
Exports to sales %00-   
Imports to sales %25.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259NA-   
Fx inflow Rs m35,384528 6,701.5%   
Fx outflow Rs m10,3997,193 144.6%   
Net fx Rs m24,985-6,665 -374.9%   
CASH FLOW
From Operations Rs m11,4932,360 487.0%  
From Investments Rs m-11,3723,008 -378.0%  
From Financial Activity Rs m-93-5,108 1.8%  
Net Cashflow Rs m28260 10.9%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 11.8 10.2 115.7%  
FIIs % 19.0 23.8 79.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 15.4 111.7%  
Shareholders   31,796 102,036 31.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SHASUN PHARMA  WYETH LTD  TORRENT PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Energy & PSU Stocks Lose(09:30 am)

Asian stocks are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 1.67% while the Hang Seng is down 0.87%. The Nikkei 225 is trading down by 1.18%.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 22, 2018 10:09 AM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS